Pfizer, Astellas Padcev combo shows overall survival benefit in urothelial cancer

Urinary bladder cancer with organs and tumors or cancerous cells 3D rendering illustration with male body. Anatomy, oncology, biomedical, disease, medical, biology, science, healthcare concepts.

libre de droit

  • A combination of Pfizer (NYSE:PFE) and Astellas’ (OTCPK:ALPMF)(OTCPK:ALPMY) antibody-drug conjugate Padcev (enfortumab vedotin-ejfv) with Merck’s (MRK) Keytruda (pembrolizumab) demonstrated a sustained overall survival and progression-free survival benefit as a first-line therapy for urothelial cancer.
  • Data showed that Padcev + Keytruda reduced the

Leave a Reply

Your email address will not be published. Required fields are marked *